相关实验视频

Updated: Jun 18, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

在NTRK融合阳性癌症中降低耐药性

Abigail G Parrish¹, Frank Szulzewsky¹

¹Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.

The Journal of pathology

|July 29, 2024

概括

研究人员开发了NTRK融合阳性软组织肉瘤的新模型,以研究对氨酸激酶抑制剂的耐药性. 他们发现了一种新的NF2基因突变导致耐药性,这表明MEK和mTOR抑制剂作为组合疗法.

科学领域:

在瘤学瘤学.
分子病理学分子病理学
遗传学遗传学是一个

背景情况:

具有NTRK融合阳性的软组织肉瘤是罕见但具有攻击性的瘤.
针对性治疗,如氨酸激酶抑制剂 (TKIs) 是有前途的,但可能会产生耐药性.
了解耐药机制对于改善治疗策略至关重要.

研究的目的:

建立NTRK融合阳性软组织肉瘤的患者衍生外生模型.
描述耐药性对TKIs的分子机制,特别是Entrectinib.
确定潜在的组合疗法,以克服TKI耐药性.

主要方法:

来自患者的ex vivo模型的开发.
将模型暴露在因特雷克提尼布度上升的环境中,以诱导耐药性.
基因组分析以确定抗性克隆中的突变.
对信号通路激活的分析 (PI3K/AKT/mTOR和Ras/Raf/MEK/ERK).
抑制剂查以确定潜在的组合剂.

主要成果:

在长时间暴露于恩特雷克提尼布后,出现了耐药克隆.
在耐药克隆中发现了NF2基因的新型失活突变.
获得的NF2突变与PI3K/AKT/mTOR和Ras/Raf/MEK/ERK信号的增加有关.
确定了MEK和mTOR抑制剂作为潜在的组合药物.

结论:

来自患者的ex vivo模型是研究软组织肉瘤中TKI耐药性的宝贵工具.
在这种背景下,NF2基因失活是抗恩特雷克提尼布抗性的新机制.
使用MEK和mTOR抑制剂的联合治疗可以克服对恩特雷克提尼布的获得性耐药性.

关键词:

NF2 NF2 是一个字母.来自患者的ex vivo细胞模型.治疗耐药性治疗耐药性氨酸激酶抑制剂氨酸激酶抑制剂

更多相关视频

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Enzyme-linked Receptors

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...